journal article·2026-03Open access

Microglial HVCN1 Deficiency Improves Movement and Survival of SOD1 G93A ALS Mice by Enhancing Microglial Migration and Neuroprotection

Fan Wang, Ke‐Yu Zhang, Lang‐Jian Zhu, Wei‐Jue Li, Yang Wu, Xiang Gao, Xiao‐Ru Ma, Xiu‐Hua Yin, Jian‐Bin Wu, Xiao‐Kang Ye, Zhao‐Jun Dong, Di‐Xian Wang, Zhe Zhou, Shao‐Dong Wang, Lei Han, Zhi‐Nong Jiang, Jing‐Wei Zhao

Advanced Science· Volume 13· Issue 13

Abstract

ABSTRACT Amyotrophic lateral sclerosis (ALS) is an incurable motor neuron disease characterized by progressive loss of motor neurons. Current clinically available drugs targeting neurons show minor survival extension and no motor improvement in ALS patients. This shifts the focus of ALS research toward non‐neuronal cells, particularly microglia, a critical driver of ALS pathogenesis. Highly druggable ion channels are key regulators of microglia function. Here, Hydrogen voltage gated channel 1 (HVCN1) was screened out as the most highly expressed ion channel in microglia, and was upregulated in microglia of SOD1 G93A mice and patients. Deletion of HVCN1 in microglia increased motor neuron survival, rescued the innervated neuromuscular junctions in the muscle, reduced glial activation and decreased the level of both misfolded protein and myelin debris in the ALS mice. Importantly, these pathological improvements were translated into significant motor improvement and survival extension in the ALS mice, exhibiting better effects than the current clinical drugs. HVCN1 deletion enhanced microglia migration and their homeostatic state with elevated neurotrophic functions. Mechanistically, HVCN1 ablation promoted microglial migration via suppressing Akt signaling. Our results identify HVCN1 as a novel promising therapeutic target for ALS, opening a new avenue to further develop specific inhibitors for HVCN1 to alleviates ALS.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Amyotrophic Lateral Sclerosis Research · Neuroinflammation and Neurodegeneration Mechanisms · Hydrogen's biological and therapeutic effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology of Sir Run Run Shaw Hospital and Department of Human Anatomy, Histology and Embryology System Medicine Research Center NHC and CAMS Key Laboratory of Medical Neurobiology Zhejiang University School of Medicine Hangzhou Zhejiang China

BGI Research Hangzhou China

BGI Research Shenzhen China

Basic Medical Experimental Teaching Center Zhejiang University School of Medicine Hangzhou Zhejiang China

National Key Discipline of Human Anatomy Southern Medical University Guangzhou China

Department of Gastroenterology Jinling Hospital Medical School of Nanjing University Nanjing China

Center of Cryo‐Electron Microscopy Zhejiang University Hangzhou Zhejiang China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (78)

Show source-provided references
1. 10.1212/CON.000000000000091110.1212/CON.0000000000000911 ↗
2. 10.1016/S0140-6736(22)01272-710.1016/S0140-6736(22)01272-7 ↗
3. 10.1038/s41582‐023‐00891‐210.1038/s41582‐023‐00891‐2 ↗
4. 10.1038/s41576-023-00592-y10.1038/s41576-023-00592-y ↗
5. 10.1136/bmj-2023-07503710.1136/bmj-2023-075037 ↗
6. 10.1002/14651858.CD001447.pub310.1002/14651858.CD001447.pub3 ↗
7. 10.1001/jamaneurol.2021.489310.1001/jamaneurol.2021.4893 ↗
8. 10.1056/NEJMoa220470510.1056/NEJMoa2204705 ↗
9. 10.1007/s00415‐024‐12437‐710.1007/s00415‐024‐12437‐7 ↗
10. 10.1007/s10072‐025‐07994‐210.1007/s10072‐025‐07994‐2 ↗
11. 10.1038/s41392‐023‐01588‐010.1038/s41392‐023‐01588‐0 ↗
12. 10.1016/j.cell.2019.08.05310.1016/j.cell.2019.08.053 ↗
13. 10.1002/ana.2525110.1002/ana.25251 ↗
14. 10.1371/journal.pone.003921610.1371/journal.pone.0039216 ↗
15. 10.1016/j.nbd.2003.12.01210.1016/j.nbd.2003.12.012 ↗
16. 10.1038/s41593-018-0242-x10.1038/s41593-018-0242-x ↗
17. 10.1016/j.neuint.2020.10492510.1016/j.neuint.2020.104925 ↗
18. 10.1016/j.tins.2018.12.00710.1016/j.tins.2018.12.007 ↗
19. 10.3390/jcm1006123910.3390/jcm10061239 ↗
20. 10.1007/s00018‐022‐04461‐510.1007/s00018‐022‐04461‐5 ↗
21. 10.1016/j.bbi.2018.07.00210.1016/j.bbi.2018.07.002 ↗
22. 10.1093/hmg/ddt25910.1093/hmg/ddt259 ↗
23. 10.1038/s41573‐022‐00612‐210.1038/s41573‐022‐00612‐2 ↗
24. 10.1523/JNEUROSCI.1860‐14.201410.1523/JNEUROSCI.1860‐14.2014 ↗
25. 10.1038/nn.305910.1038/nn.3059 ↗
26. 10.3389/fncel.2021.76805910.3389/fncel.2021.768059 ↗
27. 10.1007/s12264‐023‐01053‐610.1007/s12264‐023‐01053‐6 ↗
28. 10.1111/jnc.1492510.1111/jnc.14925 ↗
29. 10.1038/s41422‐022‐00616‐y10.1038/s41422‐022‐00616‐y ↗
30. 10.3390/antiox1203058210.3390/antiox12030582 ↗
31. 10.1172/JCI13974110.1172/JCI139741 ↗
32. 10.1038/s41586-022-04424-710.1038/s41586-022-04424-7 ↗
33. 10.1038/s41586-022-04436-310.1038/s41586-022-04436-3 ↗
34. 10.1002/brb3.7510.1002/brb3.75 ↗
35. 10.3389/fncel.2022.104564710.3389/fncel.2022.1045647 ↗
36. 10.1016/j.isci.2024.10887210.1016/j.isci.2024.108872 ↗
37. 10.1016/j.tins.2021.04.00810.1016/j.tins.2021.04.008 ↗
38. 10.1002/ana.2430410.1002/ana.24304 ↗
39. 10.1016/j.immuni.2017.08.00810.1016/j.immuni.2017.08.008 ↗
40. 10.1016/j.it.2020.07.00310.1016/j.it.2020.07.003 ↗
41. 10.1038/s41467‐024‐49596‐010.1038/s41467‐024‐49596‐0 ↗
42. 10.1016/j.cell.2022.12.03210.1016/j.cell.2022.12.032 ↗
43. 10.1093/jmcb/mjt02810.1093/jmcb/mjt028 ↗
44. 10.1182/blood.201900049510.1182/blood.2019000495 ↗
45. 10.1016/j.cell.2020.09.06410.1016/j.cell.2020.09.064 ↗
46. Siddique N. · 1
47. 10.1186/s13041‐023‐01070‐610.1186/s13041‐023‐01070‐6 ↗
48. 10.1073/pnas.212075011910.1073/pnas.2120750119 ↗
49. 10.1016/j.neuron.2014.01.01310.1016/j.neuron.2014.01.013 ↗
50. 10.1016/j.omtm.2024.10131210.1016/j.omtm.2024.101312 ↗
51. 10.1016/j.it.2020.07.00110.1016/j.it.2020.07.001 ↗
52. 10.1016/j.neuron.2014.02.04010.1016/j.neuron.2014.02.040 ↗
53. 10.1080/21678421.2019.163234610.1080/21678421.2019.1632346 ↗
54. 10.3389/fphar.2022.105400610.3389/fphar.2022.1054006 ↗
55. 10.1016/j.celrep.2013.06.01810.1016/j.celrep.2013.06.018 ↗
56. 10.3390/ijms2608385410.3390/ijms26083854 ↗
57. 10.1016/j.neuroscience.2024.11.05310.1016/j.neuroscience.2024.11.053 ↗
58. 10.1172/jci.insight.14781410.1172/jci.insight.147814 ↗
59. 10.1371/journal.pone.022752210.1371/journal.pone.0227522 ↗
60. 10.1038/ni.184310.1038/ni.1843 ↗
61. 10.1016/j.bbrc.2017.06.19710.1016/j.bbrc.2017.06.197 ↗
62. 10.1084/jem.2009183710.1084/jem.20091837 ↗
63. 10.1007/s12640‐019‐0003‐y10.1007/s12640‐019‐0003‐y ↗
64. 10.4049/jimmunol.160151510.4049/jimmunol.1601515 ↗
65. 10.1016/j.cell.2017.04.00110.1016/j.cell.2017.04.001 ↗
66. Protein Kinase Inhibitors for Amyotrophic Lateral Sclerosis Therapy (vol 178, pg 1316, 2021)
67. 10.1016/j.neuron.2018.05.01410.1016/j.neuron.2018.05.014 ↗
68. 10.3389/fncel.2022.81643910.3389/fncel.2022.816439 ↗
69. 10.1038/s41467‐018‐07548‐510.1038/s41467‐018‐07548‐5 ↗
70. 10.1016/j.bbrc.2012.01.02610.1016/j.bbrc.2012.01.026 ↗
71. Amelioration of Amyotrophic Lateral Sclerosis in SOD1G93A Mice by M2Microglia From Transplanted Marrow
72. 10.1016/j.jcyt.2022.02.00110.1016/j.jcyt.2022.02.001 ↗
73. 10.1172/JCI6263610.1172/JCI62636 ↗
74. 10.3791/2610‐v10.3791/2610‐v ↗
75. The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
76. 10.3389/fncel.2023.108218010.3389/fncel.2023.1082180 ↗
77. 10.1002/cpim.7010.1002/cpim.70 ↗
78. 10.1038/nmeth.312510.1038/nmeth.3125 ↗